Renaissance Technologies (RenTech)'s PRLD Position Overview
Renaissance Technologies (RenTech) (via Renaissance Technologies LLC (Rentech)) currently holds 271,300 shares of Prelude Therapeutics Incorporated (PRLD) worth $786,770, representing 0.00% of the portfolio. First purchased in 2021-Q4, this medium-term investment has been held for 17 quarters.
Based on 13F filings, Renaissance Technologies (RenTech) has maintained a strategic position in PRLD, demonstrating sustained confidence in this investment. Largest addition occurred in Q4 2024, adding 437,600 shares. Largest reduction occurred in Q4 2025, reducing 272,700 shares.
Analysis based on 13F filings available since 2013 Q2
Renaissance Technologies (RenTech)'s Prelude Therapeutics Incorporated (PRLD) Holding Value Over Time
Track share changes against reported price movement
Quarterly Prelude Therapeutics Incorporated (PRLD) Trades by Renaissance Technologies (RenTech)
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | -272,700 | Reduce 50.13% | 271,300 | $2.90 |
| Q3 2025 | -37,800 | Reduce 6.50% | 544,000 | $1.44 |
| Q2 2025 | -74,900 | Reduce 11.41% | 581,800 | $0.81 |
| Q1 2025 | +22,200 | Add 3.50% | 656,700 | $0.77 |
| Q4 2024 | +437,600 | Add 222.24% | 634,500 | $1.28 |
| Q3 2024 | -9,700 | Reduce 4.70% | 196,900 | $2.07 |
| Q2 2024 | -38,200 | Reduce 15.60% | 206,600 | $3.81 |
| Q1 2024 | +28,400 | Add 13.12% | 244,800 | $4.74 |
| Q4 2023 | +77,026 | Add 55.27% | 216,400 | $4.27 |
| Q3 2023 | -43,926 | Reduce 23.96% | 139,374 | $3.09 |
| Q2 2023 | +44,800 | Add 32.35% | 183,300 | $0.00 |
| Q1 2023 | +2,000 | Add 1.47% | 138,500 | $0.01 |
| Q4 2022 | -6,900 | Reduce 4.81% | 136,500 | $0.01 |
| Q3 2022 | -17,086 | Reduce 10.65% | 143,400 | $6.61 |
| Q2 2022 | +120,386 | Add 300.21% | 160,486 | $5.22 |
| Q1 2022 | -87,100 | Reduce 68.47% | 40,100 | $6.91 |
| Q4 2021 | +127,200 | New Buy | 127,200 | $12.45 |
Renaissance Technologies (RenTech)'s Prelude Therapeutics Incorporated Investment FAQs
Renaissance Technologies (RenTech) first purchased Prelude Therapeutics Incorporated (PRLD) in Q4 2021, acquiring 127,200 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Renaissance Technologies (RenTech) has held Prelude Therapeutics Incorporated (PRLD) for 17 quarters since Q4 2021.
Renaissance Technologies (RenTech)'s largest addition to Prelude Therapeutics Incorporated (PRLD) was in Q4 2024, adding 634,500 shares worth $808,988.
According to the latest 13F filing for Q4 2025, Renaissance Technologies (RenTech)'s firm, Renaissance Technologies LLC (Rentech), owns 271,300 shares of Prelude Therapeutics Incorporated (PRLD), valued at approximately $786,770.
As of the Q4 2025 filing, Prelude Therapeutics Incorporated (PRLD) represents approximately 0.00% of Renaissance Technologies (RenTech)'s publicly disclosed stock portfolio, making it one of their key holdings.
Renaissance Technologies (RenTech)'s peak holding in Prelude Therapeutics Incorporated (PRLD) was 656,700 shares, as reported at the end of Q1 2025.